MARKET-DISCOVERED GROUP
Price direction is split across 12 measured members. Capital-flow agreement is 20%, so the basket is not yet clean.
No session event has enough timestamp precision to place on the clock.
TUE, NOV 18ACM filing documented shared operating contextrestructuring · date precision only
MON, MAR 9ESPR filing documented shared operating contextrestructuring · date precision only
01 · WHAT IS HAPPENING
Observed intraday paths are not available for this group yet.
02 · WHY IT MATTERS
No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.
Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across ACM, ADPT, AKTX, CBLL, ESPR, MRVI, PSNL, TDUP, TWST, TXG.
“If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, as well as additional oversight, and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws.”
ESPR 10-K · 2026-03-10
“The increase in interest expense was primarily attributable to interest on our royalty sale liability and Loan, partially offset by lower convertible debt interest due to the payback of our 2020 Notes in November 2025.”
ESPR 10-Q · 2026-05-08
“The decrease in tax expense for the current period compared to the corresponding period last year was due primarily to the tax impact of a decrease in pre-tax income of $394.6 million, a deferred tax benefit of $54.7 million related to tax attributes that are expected to be utilized in the future that resulted from legal entity restructuring implemented in the second quarter of fiscal 2026, and a decrease in tax expense of $24.1 million related to state income taxes, partially offset by tax expense of $31.0 million related to changes in uncertain tax positions and a tax benefit of $20.1 million related to deferred tax assets recognized due to legal entity restructuring implemented in the first quarter of fiscal 2025.”
ACM 10-Q · 2026-08-11
No qualified cross-asset lead/lag link is available for this group.
Filing-linked outsiders test whether the move is spreading beyond the established cohort.
03 · WHO IS IN IT
12/21 active11 rising · 1 falling
| TICKER | Company | Role now | Today | Observed history | Trader interpretation |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics, Inc. | Most unusual | — | 90.9% of 11 sessions | Most unusual activity in this snapshot; performance direction may differ. |
| ITRI | Itron, Inc. | Participating | +1.5% | 18.2% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| STVN | Stevanato Group S.p.A. | Participating | +1.2% | 27.3% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| CORT | Corcept Therapeutics Incorporated | Participating | +1.1% | 9.1% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| SPHR | Sphere Entertainment Co. | Participating | +1.4% | 9.1% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| BUR | Burford Capital Limited | Participating | — | 9.1% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| VCYT | Veracyte, Inc. | Participating | +1.3% | 9.1% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| MSGE | Madison Square Garden Entertainment Corp. | Participating | +0.5% | 0% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| AKTX | Akari Therapeutics Plc | Participating | — | 0% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| MRVI | Maravai LifeSciences Holdings, | Participating | — | 27.3% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| PSNL | Personalis, Inc. | Participating | — | 0% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| TWST | Twist Bioscience Corporation | Participating | +6.8% | 0% of 11 sessions | Price participation is not yet confirmed by per-name flow. |
| TDUP | ThredUp Inc. | Quiet / lagging | — | 9.1% of 11 sessions | Not participating yet; a breadth test or a genuine divergence. |
| ZBRA | Zebra Technologies Corporation | Quiet / lagging | +2.3% | 0% of 11 sessions | Not participating yet; a breadth test or a genuine divergence. |
| TXG | 10x Genomics, Inc. | Quiet / lagging | +1.9% | 9.1% of 11 sessions | Not participating yet; a breadth test or a genuine divergence. |
| FIVE | Five Below, Inc. | Quiet / lagging | +5.9% | 0% of 11 sessions | Not participating yet; a breadth test or a genuine divergence. |
| ADPT | Adaptive Biotechnologies Corporation | Quiet / lagging | +2.2% | 0% of 11 sessions | Not participating yet; a breadth test or a genuine divergence. |
| ACM | AECOM | Quiet / lagging | -0.6% | 0% of 11 sessions | Not participating yet; a breadth test or a genuine divergence. |
| REAL | The RealReal, Inc. | Quiet / lagging | — | 9.1% of 11 sessions | Not participating yet; a breadth test or a genuine divergence. |
| CBLL | CeriBell, Inc. | Quiet / lagging | — | 27.3% of 11 sessions | Not participating yet; a breadth test or a genuine divergence. |
| CHAI | Core AI Holdings, Inc. | Quiet / lagging | — | 0% of 11 sessions | Not participating yet; a breadth test or a genuine divergence. |
04 · HAS THIS HAPPENED BEFORE
No completed point-in-time outcome is available yet. New live confirmations are now retained with their exact observation timestamp; statistics appear only after the corresponding candles complete.
Only 3 completed episodes across 11 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.